RYTM insider ownership: who sold, why, and what they still hold

What stands out

Selling picked up in the last 90 days: officers and directors sold 258K shares, against an average of 36K per 90 days earlier in the period. Most of it was Jennifer Lee (76K shares in the last 90 days) and Hunter Smith (63K shares in the last 90 days); 100% of these sales were under disclosed plans.Jennifer Lee: largest recent sale, Aug 13, 2026 · Hunter Smith: largest recent sale, Aug 31, 2026

A share of stake is shown for 0 of the 9 officers and directors who sold. 17 are left out

Left out: David Meeker, Hunter Smith, Yann Mazabraud, Pamela Cramer, Edward Mathers, Joseph Shulman, Christophe Jean, David McGirr, Jennifer Good, Stuart Arbuckle, Camille Bedrosian, Lynn Tetrault, Jennifer Lee, Alastair Garfield, Christopher German, Kimberly Popovits and Manher Joshi (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Jennifer Lee

EVP, Head of North America

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$8.9MDisclosed plan

Hunter Smith

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$8.8MDisclosed plan

Yann Mazabraud

EVP, Head of International

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$6.6MDisclosed plan

David Meeker

President and CEO, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.1MDisclosed plan

Lynn Tetrault

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.7MDisclosed plan

All 9 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 14, 2026David Meeker sold 50K shares ($5.1M) under a disclosed trading plan. 50K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
David Meeker President and CEO, Director	50,000	$102.67	n/a	n/a	Sep 14, 2026	Sep 14, 2026

Common questions

Is the Rhythm Pharmaceuticals, Inc. CEO selling stock?

Yes. David Meeker sold 50K shares ($5.1M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Rhythm Pharmaceuticals, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 98% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 2% had no disclosed plan. A trading plan schedules sales in advance.

Are any Rhythm Pharmaceuticals, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold9 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Jennifer Lee EVP, Head of North America	$8.9M 76K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Hunter Smith Chief Financial Officer	$8.8M 84K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Yann Mazabraud EVP, Head of International	$6.6M 57K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
David Meeker President and CEO, Director	$5.1M 50K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Lynn Tetrault Director	$3.7M 37K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Pamela Cramer Chief Human Resources Officer	$3.0M 30K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Joseph Shulman Chief Technical Officer	$2.1M 18K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Christopher German Corporate Controller & CAO	$931K 10K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Alastair Garfield Chief Scientific Officer	$913K 7.8K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 17 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

David Meeker

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for David Meeker are complete.

President and CEO, Director

n/a

−50K

n/a

Vesting, gifts, unvested awards and holding lines for David Meeker

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Meeker are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−32Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,431	$6.05	Feb 7, 2027	$1.5M
259,000	$49.23	Feb 15, 2034	$14.5M
200,000	$56.69	Feb 13, 2035	$9.7M
107,850	$98.47	Feb 10, 2036	$725K

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Hunter Smith

Chief Financial Officer

n/a

−84K

n/a

Vesting, gifts, unvested awards and holding lines for Hunter Smith

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Hunter Smith are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−11Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,813	$25.79	Feb 13, 2028	$303K
100,594	$6.88	Aug 8, 2027	$9.9M
80,400	$49.23	Feb 15, 2034	$4.5M
62,500	$56.69	Feb 13, 2035	$3.0M
37,500	$98.47	Feb 10, 2036	$252K
91,401	$6.80	Feb 8, 2032	$9.0M
79,000	$17.87	Feb 13, 2030	$6.9M

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Yann Mazabraud

EVP, Head of International

n/a

−57K

n/a

Vesting, gifts, unvested awards and holding lines for Yann Mazabraud

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Yann Mazabraud are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
67,000	$49.23	Feb 15, 2034	$3.7M
60,000	$56.69	Feb 13, 2035	$2.9M
25,000	$22.28	Oct 4, 2030	$2.1M
35,000	$94.94	Mar 1, 2036	$359K
35,875	$6.80	Feb 8, 2032	$3.5M

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Pamela Cramer

Chief Human Resources Officer

n/a

−30K

n/a

Vesting, gifts, unvested awards and holding lines for Pamela Cramer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Pamela Cramer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−4.7Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
40,200	$49.23	Feb 15, 2034	$2.2M
5,257	$19.02	Jul 25, 2031	$453K
30,000	$56.69	Feb 13, 2035	$1.5M
3,520	$6.80	Feb 8, 2032	$346K
8,375	$27.35	Jan 31, 2033	$652K
17,500	$98.47	Feb 10, 2036	$118K

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Edward Mathers

Director

n/a

Vesting, gifts, unvested awards and holding lines for Edward Mathers

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Edward Mathers are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,000	$41.39	Jun 17, 2034	$893K
7,037	$63.66	Jun 23, 2035	$292K

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Joseph Shulman

Chief Technical Officer

n/a

−18K

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Shulman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Shulman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−6.5Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,625	$21.38	Jul 26, 2030	$890K
31,875	$6.80	Feb 8, 2032	$3.1M
23,032	$27.35	Jan 31, 2033	$1.8M
50,250	$49.23	Feb 15, 2034	$2.8M
31,875	$6.80	Feb 8, 2032	$3.1M
1,297	$21.38	Jul 26, 2030	$109K
19,922	$6.80	Feb 8, 2032	$2.0M
37,500	$56.69	Feb 13, 2035	$1.8M
5,945	$6.80	Feb 8, 2032	$585K
12,563	$27.35	Jan 31, 2033	$978K
22,500	$98.47	Feb 10, 2036	$151K

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Christophe Jean

Director

n/a

Vesting, gifts, unvested awards and holding lines for Christophe Jean

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christophe Jean are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,000	$41.39	Jun 17, 2034	$893K
7,037	$63.66	Jun 23, 2035	$292K
3,691	$107.55	Jun 23, 2036	$0

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

David McGirr

Director

n/a

Vesting, gifts, unvested awards and holding lines for David McGirr

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David McGirr are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,000	$41.39	Jun 17, 2034	$893K
7,037	$63.66	Jun 23, 2035	$292K
3,691	$107.55	Jun 23, 2036	$0

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Jennifer Good

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jennifer Good

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jennifer Good are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,000	$41.39	Jun 17, 2034	$893K
7,037	$63.66	Jun 23, 2035	$292K
3,691	$107.55	Jun 23, 2036	$0

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Stuart Arbuckle

Director

n/a

Vesting, gifts, unvested awards and holding lines for Stuart Arbuckle

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Stuart Arbuckle are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,000	$41.39	Jun 17, 2034	$893K
7,037	$63.66	Jun 23, 2035	$292K
3,691	$107.55	Jun 23, 2036	$0

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Camille Bedrosian

Director

n/a

Vesting, gifts, unvested awards and holding lines for Camille Bedrosian

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Camille Bedrosian are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,000	$41.39	Jun 17, 2034	$893K
7,037	$63.66	Jun 23, 2035	$292K

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Lynn Tetrault

Director

n/a

−37K

n/a

Vesting, gifts, unvested awards and holding lines for Lynn Tetrault

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lynn Tetrault are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,000	$41.39	Jun 17, 2034	$893K
7,037	$63.66	Jun 23, 2035	$292K
3,691	$107.55	Jun 23, 2036	$0

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Jennifer Lee

EVP, Head of North America

n/a

−76K

n/a

Vesting, gifts, unvested awards and holding lines for Jennifer Lee

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jennifer Lee are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−9.2Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
71,283	$24.29	Nov 8, 2030	$5.8M
37,108	$30.66	Feb 10, 2031	$2.8M
21,601	$6.80	Feb 8, 2032	$2.1M
67,000	$49.23	Feb 15, 2034	$3.7M
55,000	$56.69	Feb 13, 2035	$2.7M
32,500	$98.47	Feb 10, 2036	$218K
36,283	$24.29	Nov 9, 2030	$2.9M

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Alastair Garfield

Chief Scientific Officer

n/a

−7.8K

n/a

Vesting, gifts, unvested awards and holding lines for Alastair Garfield

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alastair Garfield are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−4.2Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
53,333	$43.76	Jul 7, 2034	$3.3M
40,000	$56.69	Feb 13, 2035	$1.9M
25,000	$98.47	Feb 10, 2036	$168K

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Christopher German

Corporate Controller & CAO

n/a

−10K

n/a

Vesting, gifts, unvested awards and holding lines for Christopher German

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher German are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−1.5Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,400	$49.23	Feb 15, 2034	$302K
3,713	$56.69	Feb 13, 2035	$180K
2,325	$17.97	Apr 3, 2033	$203K
2,701	$49.23	Feb 15, 2034	$151K

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Kimberly Popovits

Director

n/a

Vesting, gifts, unvested awards and holding lines for Kimberly Popovits

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kimberly Popovits are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,257	$88.12	Mar 31, 2036	$175K

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Manher Joshi

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Manher Joshi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Manher Joshi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,000	$115.44	Aug 16, 2036	$0

Estimate: options held × ($105.19 − strike price), using the most recent insider trade price on Form 4 (Sep 14, 2026), not a market close.

Holdings and share of stake for Rhythm Pharmaceuticals, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$40.1M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $40.1M across 369,489 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $39.2M · 98%

The lighter segment is sales with no plan disclosed in the filing ($931K), including tax-related sales outside a plan.

No plan disclosed · $931K

Sales with no 10b5-1 plan and no tax reference in the filing. $931K of it is Christopher German. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Christopher German, Mar 4, 2026

Taxes

68,403 shares ($7.5M) were withheld by the company for taxes, which isn't a market sale.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Jennifer Lee EVP, Head of North America	76K	$8.9M	100%	22%	Aug 13, 2026 to Aug 13, 2026
Hunter Smith Chief Financial Officer	84K	$8.8M	100%	22%	Feb 4, 2026 to Aug 31, 2026
Yann Mazabraud EVP, Head of International	57K	$6.6M	100%	17%	Aug 12, 2026 to Aug 12, 2026
David Meeker President and CEO, Director	50K	$5.1M	100%	13%	Sep 14, 2026 to Sep 14, 2026
Lynn Tetrault Director	37K	$3.7M	100%	9%	Jun 22, 2026 to Jun 22, 2026
Pamela Cramer Chief Human Resources Officer	30K	$3.0M	100%	7%	Nov 7, 2025 to Dec 11, 2025
Joseph Shulman Chief Technical Officer	18K	$2.1M	100%	5%	Oct 28, 2025 to Aug 13, 2026
Christopher German Corporate Controller & CAO	10K	$931K	0%	2%	Mar 4, 2026 to May 15, 2026
Alastair Garfield Chief Scientific Officer	7.8K	$913K	100%	2%	Aug 13, 2026 to Aug 13, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$1.4M	$1.4M	$0	$0
Nov 2025	$2.6M	$2.6M	$0	$0
Dec 2025	$372K	$372K	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$2.2M	$2.2M	$0	$0
Mar 2026	$503K	$0	$0	$503K
Apr 2026	$0	$0	$0	$0
May 2026	$428K	$0	$0	$428K
Jun 2026	$3.7M	$3.7M	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$23.7M	$23.7M	$0	$0
Sep 2026	$5.1M	$5.1M	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

In line with the past 5 years. 9 insiders sold; the average is 6 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	369K	9	$40.1M
Oct 16, 2025 1 year earlier	542K	9	$37.3M
Oct 16, 2024 2 years earlier	563K	9	$24.5M
Oct 17, 2023 3 years earlier	31K	6	$792K
Oct 17, 2022 4 years earlier	26K	6	$406K
Oct 17, 2021 5 years earlier	1.00M	1	$25.1M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty17 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Rhythm Pharmaceuticals, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology430 filings on record, 51 filed in the 12-month period, and how we read them

All 430 Forms 3, 4 and 5 on record for Rhythm Pharmaceuticals, Inc. (SEC CIK 1649904), filed from Oct 4, 2017 to Sep 14, 2026; 51 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (29)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
William Roberts	Mar 31, 2023	7,872 shares, last reported balance as of Mar 29, 2023
Linda Manning	Feb 11, 2022	No balance on record
Todd Foley	Mar 16, 2021	909,258 shares, last reported balance as of Mar 15, 2021
Simon Kelner	Feb 16, 2021	100 shares, last reported balance as of Jun 6, 2018
Murray Stewart	Feb 16, 2021	No balance on record
RA CAPITAL MANAGEMENT, L.P.	Dec 4, 2020	9,501,268 shares, last reported balance as of Dec 3, 2020
Nithya Desikan	Sep 1, 2020	43,602 shares, last reported balance as of Aug 31, 2020
Keith Gottesdiener	Mar 11, 2020	558,250 shares, last reported balance as of Mar 9, 2020
Ploeg Van der	Jun 3, 2019	42,339 shares, last reported balance as of May 31, 2019
THIRD ROCK VENTURES LP	Sep 4, 2018	297,315 shares, last reported balance as of Aug 30, 2018
Neil Exter	Jun 8, 2018	No balance on record
Neil Exter	Jun 8, 2018	No balance on record
ORBIMED ADVISORS LLC	May 24, 2018	2,750,079 shares, last reported balance as of May 22, 2018
Fred Fiedorek	Feb 16, 2018	131,899 shares, last reported balance as of Oct 4, 2017
MPM BIOVENTURES V, L.P.	Oct 11, 2017	2,696,392 shares, last reported balance as of Oct 10, 2017
PFIZER INC	Oct 10, 2017	1,427,639 shares, last reported balance as of Oct 10, 2017
S.A Ipsen	Oct 10, 2017	1,646,198 shares, last reported balance as of Oct 10, 2017
Hadley Harbor Master Investors (Cayman) L.P.	Oct 10, 2017	545,256 shares, last reported balance as of Oct 10, 2017
James Barrett	Oct 10, 2017	4,909,956 shares, last reported balance as of Oct 10, 2017
Peter Barris	Oct 10, 2017	4,909,956 shares, last reported balance as of Oct 10, 2017
Forest Baskett	Oct 10, 2017	4,909,956 shares, last reported balance as of Oct 10, 2017
Patrick Kerins	Oct 10, 2017	4,909,956 shares, last reported balance as of Oct 10, 2017
David Mott	Oct 10, 2017	4,909,956 shares, last reported balance as of Oct 10, 2017
NEW ENTERPRISE ASSOCIATES 13 LP	Oct 10, 2017	4,909,956 shares, last reported balance as of Oct 10, 2017
Scott Sandell	Oct 10, 2017	4,909,956 shares, last reported balance as of Oct 10, 2017
Ravi Viswanathan	Oct 10, 2017	4,909,956 shares, last reported balance as of Oct 10, 2017
James Flynn	Oct 10, 2017	937,010 shares, last reported balance as of Oct 10, 2017
BAKER BROS. ADVISORS LP	Oct 6, 2017	2,049,020 shares, last reported balance as of Oct 5, 2017
Jonathan Silverstein	Oct 4, 2017	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Rhythm Pharmaceuticals, Inc. insiders sold $40.1M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Rhythm Pharmaceuticals, Inc. CEO selling stock?

Why are Rhythm Pharmaceuticals, Inc. insiders selling?

Are any Rhythm Pharmaceuticals, Inc. insiders buying?

The evidence

No plan disclosed · $931K

Taxes

Sales by month